Pfizer Develops Chesterfield and Ann Arbor Campuses

Published March 2006

CHESTERFIELD, MO. -

Pfizer has selected Gilbane Building Company in a joint venture with Tarlton Corporation as the Construction Manager for Pfizer's new research facility in Chesterfield, Mo. The four-story, 330,000-sf facility is part of a nearly $200-million expansion of Pfizer's existing four-building site. Gilbane's Chicago office and Tarlton's St. Louis office will oversee the project with the design team of Kling Architects. The Gilbane-Tarleton team will help Pfizer construct an integrated R&D facility that brings all of its scientific wok to a single location. A four-story glass curtain wall will connect the new research facility, known as Building CC, to Building AA and BB, the two existing Pfizer pharmaceutical research buildings. This expanded capacity will allow the company to relocate approximately 250 employees from throughout the St. Louis region to its Chesterfield campus, bringing the total workforce at the site to just over 1,000. The project is expected to reach completion by the end of 2008.

Additionally, Pfizer is engaged in a renovation of its Ann Arbor, Mich., campus. A $73-million toxicology-testing facility renovation began over a year ago and is slated for completion in September of 2006. Pfizer is also in the early stages of adding lab and warehouse space to its Technical Development Facility which accommodates drug compound testing. The $30-million project is expected to reach completion in 2006. The Ann Arbor renovation will enable Pfizer to consolidate employees from multiple off-site leased locations.

Copyright 2008 Tradeline Inc.
All Rights Reserved
ISSN: 1096-4894